- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07222553
Studie för att utvärdera farmakokinetik, farmakodynamik, säkerhet och tolerabilitet av Inebilizumab hos pediatriska deltagare med IgG4-RD
Öppen, okontrollerad, multicentrisk studie för att utvärdera farmakokinetiken, farmakodynamiken, säkerheten och tolerabiliteten av inebilizumab hos barn från 2 år till under 18 år med immunoglobuling G4-relaterad sjukdom (IgG4-RD)
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Amgen Call Center
- Telefonnummer: 866-572-6436
- E-post: medinfo@amgen.com
Studieorter
-
-
Ceará
-
Fortaleza, Ceará, Brasilien, 60140-025
- Rekrytering
- Centro Oncologia Leonardo Da Vinci
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 40110-060
- Rekrytering
- Universidade Federal da Bahia - Hospital Universitario Professor Edgard Santos
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
- Rekrytering
- Hospital de Clinicas de Porto Alegre
-
-
-
-
Florida
-
Tampa, Florida, Förenta staterna, 33612
- Rekrytering
- University of South Florida - Carol and Frank Morsani Center for Advanced Health Care
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- Rekrytering
- University of North Carolina at Chapel Hill
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15224
- Rekrytering
- University of Pittsburgh Medical Center Childrens Hospital of Pittsburgh
-
-
-
-
-
Athens, Grekland, 11527
- Rekrytering
- General Children Hospital Panagioti and Aglaias Kyriakou
-
Athens, Grekland, 11521
- Rekrytering
- Euroclinic Children Hospital
-
-
-
-
-
Roma, Italien, 00165
- Rekrytering
- IRCCS Ospedale Pediatrico Bambino Gesu
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100730
- Rekrytering
- Peking Union Medical College Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kina, 401122
- Rekrytering
- Childrens Hospital of Chongqing Medical University
-
-
Hunan
-
Changsha, Hunan, Kina, 410000
- Rekrytering
- The Second Xiangya Hospital of Central South University
-
-
-
-
-
Warsaw, Polen, 04-730
- Rekrytering
- Instytut Pomnik-Centrum Zdrowia Dziecka
-
Warsaw, Polen, 03-712
- Rekrytering
- Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
-
Wroclaw, Polen, 52-114
- Rekrytering
- Szpital Specjalistyczny Im A Falkiewicza we Wroclawiu
-
-
-
-
Valencia
-
Valencia, Valencia, Spanien, 46026
- Rekrytering
- Hospital Universitari i Politecnic La Fe
-
-
-
-
-
Ankara, Turkiet (Türkiye), 06100
- Rekrytering
- Hacettepe Universitesi Tip Fakultesi Hastanesi
-
Istanbul, Turkiet (Türkiye), 34098
- Rekrytering
- Istanbul Universitesi Cerrahpasa Tip Fakultesi
-
Istanbul, Turkiet (Türkiye), 34764
- Rekrytering
- Umraniye Egitim ve Arastirma Hastanesi
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Participants must weigh ≥ 17 kg to be eligible for enrollment.
- Participant has provided informed consent/assent before initiation of any study-specific activities/procedures. Participant's legally authorized representative has provided informed consent when the participant is legally too young to provide informed consent, and the participant has provided written assent based on local regulations and/or guidelines before any study-specific activities/procedures being initiated.
- Age 2 to < 18 years at the time of screening. For participants who reach the age of legal consent during the clinical study, notification will be required, and a new consent form must be signed by the participant for continuation in the study.
- Clinical diagnosis of IgG4-RD.
- Fulfillment of the 2019 American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) classification criteria as determined by the principal investigator (PI) at screening. Specifically, participants must meet the classification criteria entry requirements (including involvement of one of the following organs: pancreas, bile ducts/biliary tree, orbits, lungs, kidneys, lacrimal glands, major salivary glands, retroperitoneum, aorta, pachymeninges, or thyroid gland [Riedel's thyroiditis]), must not meet any of the classification criteria exclusions, and must achieve at least 20 classification criteria inclusion points.
- Receipt of all age-appropriate and locally-required vaccinations before screening.
- Participants requiring treatment in addition to or other than glucocorticoids (GCs) for IgG4-RD according to PI's assessment at screening.
- Participants who are on GCs for the treatment of IgG4-RD should remain on a stable dose for at least 2 weeks before enrollment (Day 1). Tapering post enrollment will be at PI's discretion.
Key Exclusion Criteria:
-
Participants with any of the following abnormal liver function tests in the presence of hepatobiliary IgG4-RD activity:
- aspartate aminotransferase (AST) > 10 × upper limit of normal (ULN)
- alanine aminotransferase (ALT) > 10 × ULN
- total bilirubin (TBL) > 5 × ULN Screening liver function tests may be repeated before Day 1 to permit abnormal values due to hepatobiliary IgG4-RD activity to respond to GC treatment.
-
Evidence of significant hepatic, renal, or metabolic dysfunction or significant hematological abnormality, including any of the following at screening (one repeat test may be conducted to confirm results within the same screening period):
- platelet count < 75000/μL (or < 75 × 109/L)
- absolute neutrophil count < 1200 cells/μL
- total Ig < 600 mg/dL
- CD4 T lymphocyte count < 300 cells/µL
- hemoglobin < 8 g/dL (or < 80 g/L).
-
Estimated glomerular filtration rate < 45 mL/min/1.73 m^2.
-
B-cell counts < one-half of the lower limit of normal (LLN) for age according to the central laboratory.
-
Diagnosed with a concurrent autoimmune disease that is uncontrolled or requires any prohibited medication (unless approved by the medical monitor).
-
Clinically significant serious active or chronic viral, bacterial, or fungal infection that requires treatment with anti-infectives, hospitalization, or, in the investigator's opinion, represents an additional risk to the participant, within 2 months before Day 1 of study.
-
Known history of congenital or acquired immunodeficiency (eg, due to human immunodeficiency virus [HIV] infection, splenectomy, immunosuppression-related or idiopathic T-cell deficiencies) that predisposes the participant to infection.
-
Positive test for chronic hepatitis B infection at screening, defined as either: (1) Positive hepatitis B surface antigen (HBsAg); or (2) Positive hepatitis B core antibody (anti-HBc) PLUS negative hepatitis B surface antibody (anti-HBs). Note: Participants with a positive anti-HBs only, or a positive anti-HBc plus positive anti-HBs and negative HBsAg, are eligible to enroll.
-
Receipt of any of the following before Day 1: alemtuzumab, total lymphoid irradiation, bone marrow transplant, T-cell vaccination therapy.
-
Receipt of any of the following within 2 months before Day 1: azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, cyclophosphamide, tocilizumab, satralizumab, eculizumab, and mitoxantrone.
-
Receipt of rituximab or any experimental B-cell depleting agent (eg, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab), or any non-depleting B-cell-directed therapy (eg, belimumab), abatacept, within 6 months before screening unless B-cell counts have returned to ≥ one-half the LLN.
-
Receipt of any live or attenuated vaccine (administration of inactivated [killed] vaccine is acceptable) within 4 weeks before Day 1, Bacillus Calmette-Guérin vaccine within 1 year of screening, or blood transfusion within 4 weeks before screening or during screening.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Inebilizumab
Participants will receive Inebilizumab via intravenous (IV) infusion. |
Inebilizumab will be administered via IV infusion. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Maximal plasmakoncentration (Cmax) av Inebilizumab
Tidsram: Upp till dag 561
|
Upp till dag 561
|
|
Area Under the Plasma Concentration-time Curve (AUC) av Inebilizumab
Tidsram: Upp till dag 561
|
Upp till dag 561
|
|
Clearance (CL) av Inebilizumab
Tidsram: Upp till dag 561
|
Upp till dag 561
|
|
Terminal halveringstid (t½) för Inebilizumab
Tidsram: Upp till dag 561
|
Upp till dag 561
|
|
Fördelningsvolym vid jämvikt (Vss) för Inebilizumab
Tidsram: Upp till dag 561
|
Upp till dag 561
|
|
Förändring från baslinjen i CD20+ B-cellantal
Tidsram: Baseline och dag 561
|
Baseline och dag 561
|
|
Antal deltagare som upplever biverkningar (AEs)
Tidsram: Upp till dag 561
|
Upp till dag 561
|
|
Antal deltagare som upplever allvarliga biverkningar (SAE)
Tidsram: Baslinje upp till dag 561
|
Baslinje upp till dag 561
|
|
Antal deltagare som upplever intressehändelser (EOIs)
Tidsram: Baseline upp till dag 561
|
Baseline upp till dag 561
|
|
Antal deltagare som upplever kliniskt signifikanta förändringar från baslinjen i laboratorieparametrar
Tidsram: Baslinje upp till dag 561
|
Baslinje upp till dag 561
|
|
Antal deltagare som upplever kliniskt signifikanta förändringar i vitalparametrar från baslinjen
Tidsram: Baseline upp till dag 561
|
Baseline upp till dag 561
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Tid till första behandlade utbrott över 52 veckor
Tidsram: Upp till vecka 52
|
Upp till vecka 52
|
|
Andel deltagare utan försvåring under 52 veckor
Tidsram: Upp till vecka 52
|
Upp till vecka 52
|
|
Årlig förvärrad frekvens över 52 veckor
Tidsram: Upp till vecka 52
|
Upp till vecka 52
|
|
Förekomst av antidrogliknande antikroppar (ADA) före och efter behandlingsstart
Tidsram: Dag 1 till Dag 561
|
Dag 1 till Dag 561
|
|
Procentuell minskning från baslinjen i daglig glukokortikoiddos vid vecka 52
Tidsram: Baseline och vecka 52
|
Baseline och vecka 52
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: MD, Amgen
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 20240202
- 2025-520988-41-00 (Ctis)
- 2025 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Tidsram för IPD-delning
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Kriterier för IPD Sharing Access
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .